Get the Stockscreener App
1.06
6.92%
0.0686
After Hours:
1.05
-0.01
-0.94%
Elutia Inc stock is traded at $1.06, with a volume of 173.04K.
It is up +6.92% in the last 24 hours and down -3.64% over the past month.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.
See More
Previous Close:
$0.9914
Open:
$1
24h Volume:
173.04K
Relative Volume:
1.62
Market Cap:
$46.86M
Revenue:
$15.97M
Net Income/Loss:
$-24.40M
P/E Ratio:
-1.3975
EPS:
-0.7585
Net Cash Flow:
$-45.82M
1W Performance:
+10.81%
1M Performance:
-3.64%
6M Performance:
+95.32%
1Y Performance:
-40.78%
1-Day Range:
$1.00
$1.06
1-Week Range:
$0.93
$1.06
52-Week Range:
$0.50
$2.64
Elutia Inc Stock (ELUT) Company Profile
Name
Elutia Inc
Sector
Industry
Phone
240-247-1143
Address
12510 PROSPERITY DRIVE, SILVER SPRING
Compare ELUT vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELUT
Elutia Inc
|
1.06 | 46.86M | 15.97M | -24.40M | -45.82M | -0.7585 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Elutia Inc Stock (ELUT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-02-20 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-02-20 | Initiated | Cowen | Outperform |
| Nov-02-20 | Initiated | Piper Sandler | Overweight |
| Nov-02-20 | Initiated | Truist | Buy |
Elutia Inc Stock (ELUT) Latest News
Elutia Inc (ELUT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Elutia Inc (ELUT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Elutia Inc (ELUT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Elutia Inc (ELUT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Elutia Inc (ELUT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Elutia Inc (ELUT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Elutia Inc (ELUT) Institutional Confidence - TradingKey
Elutia Inc (ELUT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Elutia Inc (ELUT) Valuation: PE, PB & Fair Value Analysis - TradingKey
ELUT: Drug-eluting biologic for breast reconstruction targets high infection rates in a $1.5B market - TradingView
Elutia Q1 2026 Earnings: EPS Misses Estimates Amid Operational ChallengesBanking Earnings Report - newsline.com
Elutia shareholders approve board proposals at annual meeting - Investing.com
Elutia shareholders approve board proposals at annual meeting By Investing.com - Investing.com Nigeria
Elutia Shareholders Approve Amended Incentive Plan and Governance - TipRanks
Elutia (ELUT) investors approve equity plan amendment and annual say-on-pay - Stock Titan
Elutia Inc. (ELUT) Q1 2026 Earnings: EPS Misses Estimates as Company Navigates Early-Stage PipelineRevenue Warning Signal - newsline.com
Elutia (ELUT) grants director Kevin Rakin 159,590 stock options - Stock Titan
Elutia (NASDAQ: ELUT) director awarded 106K stock options as compensation - Stock Titan
Elutia (NASDAQ: ELUT) director receives 106,393 stock options at $0.96 strike - Stock Titan
Elutia (NASDAQ: ELUT) director Brigid Makes receives 106,393-share stock option grant - Stock Titan
ELUT Q1 2026 Earnings: EPS Misses Estimates, Stock Ticks UpNext Quarter Guidance - newsline.com
ELUT Q1 2026 Earnings: EPS Misses Estimates, Stock Edges Higher Despite SurpriseShare Dilution Risk - newsline.com
ELUTIA (ELUT) CSO reports RSU vesting and tax withholding share disposition - Stock Titan
Elutia (ELUT) CFO reports RSU vesting and tax withholding event - Stock Titan
Elutia (ELUT) CEO RSUs vest; shares withheld to cover taxes - Stock Titan
Elutia to Present at Planet MicroCap Showcase 2026 on June 17th - BioSpace
Breast reconstruction infections: Elutia to outline biomatrix tech in Vegas - Stock Titan
Elutia Inc. (ELUT) Q1 2026 Earnings: Wider-Than-Expected Loss Weighs on SharesMargin Guidance - newsline.com
Elutia Inc. (ELUT) Edges Higher: Approaching Resistance Amid Low-Volume RallyRectangle Pattern - newsline.com
Elutia Inc. (ELUT) Edges Higher: Stock Gains 3.49% as Price Approaches Key ResistanceEqual Weight ETF - newsline.com
ELUT Q1 2026 Earnings: EPS Misses Estimates as Stock Moves HigherHigh Estimate Range - newsline.com
Elutia Inc. (ELUT) Slips Nearly 5% as Stock Tests Key Support LevelsDescending Triangle - newsline.com
Elutia Inc. (ELUT) Shows Signs of Weakening Momentum Near Support LevelsOrder Block - newsline.com
Despite Elutia's Pullback, Insiders Still Gained US$75k - simplywall.st
Elutia (ELUT) director gifts shares and updates trust, HighCape stakes - Stock Titan
ELUT Q1 2026 Earnings: EPS Misses Estimates as Stock Declines Nearly 7%Profit Announcement - newsline.com
ELUT Q1 2026 Earnings: EPS Misses Estimates on Higher Operating CostsDownward Estimate Revision - newsline.com
Elutia Inc. (ELUT) Holds Near Key Support After Marginal DeclineChannel Projection - newsline.com
Elutia Stock Flat Ahead of Open as $1.5 Billion Decision Waits - Bez Kabli
Elutia Inc. (ELUT) Slips 3.33% as Stock Tests Key Support LevelsStop Run - The Legal Advocate
Elutia Inc. (ELUT) Dips 3.33% as Stock Hovers Near Critical $1.10 SupportRevenue Growth Stocks - Newser
A Reno Biotech Just Rang the Nasdaq Bell — Here’s Why the Whole Regenerative-Medicine Tape Is Worth Watching - GlobeNewswire
Elutia (ELUT) Q1 2026 Earnings Miss by Significant: Key TakeawaysEarnings Seasonality - thelegaladvocate.com
Elutia (ELUT) Q1 2026 Results: Profit Pressure, Guidance CutPost-Earnings Reaction - Newser
Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - Sahm
Elutia (ELUT) Q1 2026 Earnings Miss: EPS $-0.17 vs $-0.15 ExpectedDownward Estimate Revision - The Legal Advocate
ELUT: Antibiotic-eluting matrix targets high breast reconstruction infection rates in a $1.5B market - TradingView
Elutia Announces Grants of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Is Elutia (ELUT) Overvalued After Q1 2026? EPS Not Disclosed; Re - GuruFocus
Elutia (ELUT) Q1 2026 Earnings Transcript - AOL.com
Elutia (NASDAQ: ELUT) posts wider Q1 2026 loss while holding $28.5M cash - Stock Titan
Elutia Inc Stock (ELUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Elutia Inc Stock (ELUT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| NEELS GUIDO J | Director |
Jan 30 '26 |
Buy |
1.04 |
20,000 |
20,800 |
118,750 |
| NEELS GUIDO J | Director |
Jan 29 '26 |
Buy |
1.06 |
15,000 |
15,900 |
98,750 |
| NEELS GUIDO J | Director |
Jan 28 '26 |
Buy |
1.06 |
15,000 |
15,900 |
83,750 |
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):